Welcome to our dedicated page for Inozyme Pharma news (Ticker: INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.
Inozyme Pharma, Inc. (INZY) is a clinical-stage biopharmaceutical company pioneering enzyme replacement therapies for rare mineralization disorders. This page provides investors and healthcare stakeholders with essential updates on INZY's progress in addressing conditions like ENPP1 Deficiency and calciphylaxis through its lead candidate INZ-701.
Access consolidated news about clinical trial developments, regulatory milestones, and scientific advancements. Our repository includes press releases on study results, partnership announcements with research organizations, and analyses of INZY's therapeutic approach targeting the PPi-Adenosine pathway.
Key updates cover safety/efficacy data from ongoing trials, manufacturing collaborations, and presentations at medical conferences. Bookmark this page to efficiently track INZY's progress in developing treatments for diseases with significant unmet needs.
The ENERGY 3 trial shows promising interim data with sustained phosphate increases and favorable safety profile. At Week 39, mean phosphate levels increased by +12.1% in the INZ-701 arm versus a -9.0% decrease in conventional treatment. No patient dropouts or safety concerns were reported, with topline data expected in Q1 2026.
The company appointed Dr. Petra Duda as Chief Medical Officer, effective May 15, 2025. Financial results show cash position of $84.8 million as of March 31, 2025, with funding expected into Q1 2026. Q1 net loss was $28.0 million ($0.44/share) compared to $23.3 million ($0.38/share) in the prior year.
Notable regulatory progress includes new ICD-10 codes for ENPP1 Deficiency (effective October 2025) and agreement with Japan's PMDA on filing strategy for INZ-701.
Inozyme Pharma (INZY) has published groundbreaking research in JBMR Plus detailing the largest retrospective analysis of ENPP1 Deficiency, a rare disease affecting bone health and blood vessel function. The study, conducted in collaboration with NIH and Münster University Children's Hospital experts, analyzed 84 individuals with ENPP1 Deficiency.
Key findings revealed that the disease manifests as either Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2). Of the studied cases:
- 51 patients were diagnosed with GACI, with only 19 surviving infancy
- 22 progressed from GACI to ARHR2
- 11 initially presented with ARHR2
The research showed that by age 55, over 95% of patients develop cardiovascular, musculoskeletal, and other organ complications. 60% of patients exhibited arterial calcification within their first 3 months, and by age 10, approximately 70% developed serious musculoskeletal complications.
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases affecting bone health and blood vessel function, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's CEO and Chairman, Doug Treco, Ph.D., will engage in a fireside chat scheduled for Monday, April 7, 2025, from 2:15-2:55pm ET. Investors and interested parties can access the live webcast through the Investor Relations section of Inozyme's website under events. A replay will be available for a time following the presentation.
Inozyme Pharma (NASDAQ: INZY) reported its full year 2024 financial results and announced strategic changes. The company completed enrollment in its ENERGY 3 pivotal trial for ENPP1 Deficiency, with topline data expected in Q1 2026. To extend cash runway, Inozyme is implementing a strategic prioritization including a 25% workforce reduction.
Financial highlights include:
- Cash position of $113.1 million as of December 31, 2024
- R&D expenses increased to $83.2 million from $54.8 million in 2023
- G&A expenses remained stable at $20.8 million
- Net loss widened to $102.0 million ($1.62 per share) compared to $71.2 million ($1.37 per share) in 2023
The company reported positive interim results from ENERGY 1 trial and Expanded Access Program in infants and young children with ENPP1 Deficiency. The current cash position is expected to fund operations into Q1 2026.
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases affecting bone health and blood vessel function, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference.
The company's CEO and Chairman, Doug Treco, Ph.D., will deliver a presentation on Monday, March 3, 2025, from 1:10-1:40pm ET. Interested parties can access a live webcast of the presentation through the Investor Relations section of Inozyme's website under the events tab. A replay will be available for a time following the presentation.
Inozyme Pharma (Nasdaq: INZY) has announced that their Chief Medical Officer, Dr. Kurt Gunter, will present new data regarding INZ-701 at the CHOP Cardiology 2025 conference in Orlando, Florida. The presentation will focus on results from their Expanded Access Program (EAP) evaluating INZ-701's impact on infants and children with ENPP1 Deficiency.
The presentation, titled 'Impact of the Enzyme Replacement Therapy, INZ-701, in Children with ENPP1 Deficiency: Experience from an Expanded Access Program,' is scheduled for Saturday, February 22, 2025, from 10:00 to 11:00am ET during the poster session. The conference runs from February 19-23, 2025.
Inozyme Pharma (NASDAQ: INZY) announced positive interim data for INZ-701 in treating ENPP1 Deficiency. The interim results from ENERGY 1 trial and Expanded Access Program showed significant improvements in infants and young children, including:
- 80% survival rate beyond first year (vs. 50% historical rate)
- Reduction or stabilization of arterial calcifications
- Improved heart function
- No evidence of rickets in patients evaluated beyond one year
- Favorable safety profile with only mild injection site reactions
The company completed enrollment in the ENERGY 3 pivotal trial with 25 patients, expecting topline data in early 2026. Additionally, Inozyme received regulatory support from FDA and EMA for the planned ASPIRE pivotal trial in children with ABCC6 Deficiency, targeting approximately 70 patients, with trial initiation planned for early 2026.
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases affecting bone health and blood vessel function, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer, will engage in a fireside chat on Wednesday, December 4, 2024, from 2:30-2:55pm ET. The presentation will be accessible via live webcast through Inozyme's Investor Relations website section, with a replay available for time.
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases affecting bone health and blood vessel function, has announced its upcoming participation in two major investor conferences. Doug Treco, Ph.D., CEO and Chairman, will present at the Stifel 2024 Healthcare Conference on November 18 (3:35-4:05pm ET) and the Jefferies London Healthcare Conference on November 20 (2:30-2:55pm GMT / 9:30-9:55am ET). Live webcasts will be available through Inozyme's website's Investor Relations section, with replays accessible for a time.
FAQ
What is the current stock price of Inozyme Pharma (INZY)?
What is the market cap of Inozyme Pharma (INZY)?
